Description: Propanc Biopharma, Inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. The company's lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. Propanc Biopharma, Inc. has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.
Home Page: www.propanc.com
302, 6 Butler Street
Camberwell,
VIC
3124
Australia
Phone:
61 3 9882 0780
Officers
| Name | Title |
|---|---|
| Mr. James Nathanielsz | Exec. Chairman, CEO, CFO, Treasurer & Sec. |
| Dr. Julian Norman Kenyon ChB, M.D., MB | Chief Scientific Officer, CTO & Director |
| Prof. Klaus Kutz | Chief Medical Officer & Member of Scientific Advisory Board |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 1 |